Featured News

Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

The first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.

The Celiac Disease Foundation uses peer-reviewed research to push our federal government to act responsibly. Our sponsorship of Columbia University’s Biennial Symposium, where the world’s expert celiac researchers share their findings and collaborate on future projects, continues this work.

Dr. Dan Leffler, Celiac Disease Foundation Medical Advisory Board Member and clinician and researcher at Harvard Medical School and Takeda, spoke about the profound ineffectiveness and failure of the gluten-free diet as a treatment for celiac disease.

CEO Marilyn G. Geller speaks at the 18th International Celiac Disease Symposium (ICDS).

Often, when a patient is following a long-term gluten-free diet with good compliance, micronutrient deficiencies cannot be detected. This review - published in the scientific journal Medicina - evaluates the most recent literature on micronutrient deficiencies in patients following a long-term gluten-free diet in order to provide dietary supplementation advice. The study concludes that in patients with micronutrient deficiencies caused by celiac disease, vitamin supplements may be necessary.

To ensure our community gets the representation it deserves, we are delighted to announce that we have retained Ben Nicholson, a consultant based in Washington, DC, to provide legislative, policy, and advocacy services for the Foundation.